IL1B and COVID-19: Considering the pathological role of IL-1β signaling in CS, several drugs targeting IL-1β signaling, including IL-1β antagonist canakinumab and IL-1 receptor antagonist anakinra, may offer clinical benefits in the treatment of COVID-19, particularly in CS.